Checkpoint Therapeutics (NASDAQ:CKPT) Releases Earnings Results, Misses Estimates By $0.47 EPS

Checkpoint Therapeutics (NASDAQ:CKPT) announced its quarterly earnings results on Friday. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.47), Zacks reports.

Checkpoint Therapeutics Trading Up 0.2 %

Shares of NASDAQ CKPT opened at $4.04 on Friday. The stock has a market capitalization of $197.29 million, a price-to-earnings ratio of -2.20 and a beta of 1.41. Checkpoint Therapeutics has a 12-month low of $1.38 and a 12-month high of $4.50. The firm’s 50-day moving average price is $3.32 and its 200-day moving average price is $3.26.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Lake Street Capital reaffirmed a “hold” rating and issued a $4.10 target price (down from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. D. Boral Capital reaffirmed a “buy” rating and issued a $4.80 price objective (down previously from $9.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th.

Insiders Place Their Bets

In related news, CFO William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the transaction, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at approximately $5,353,223.48. The trade was a 4.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James F. Oliviero III sold 9,233 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $3.41, for a total transaction of $31,484.53. Following the transaction, the chief executive officer now owns 3,785,350 shares in the company, valued at $12,908,043.50. The trade was a 0.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 93,674 shares of company stock valued at $336,011 over the last ninety days. 2.10% of the stock is owned by insiders.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.